0001213660 false 0001213660 2023-08-07 2023-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 7, 2023

 

BIMI International Medical Inc.
(Exact name of registrant as specified in its charter)

 

Delaware   001-34890   02-0563302
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

725 5th Avenue, 15th Floor, 15-01

New York NY

  10022
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 212 542 0028

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   BIMI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01.Other Events.

On August 7, 2023, BIMI International Medical Inc. (the “Company” or the “Registrant”) issued a press release announcing strategic partnership by its Phenix Bio Inc. subsidiary with China Duty Free Group. A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01.Financial Statement and Exhibits.

Exhibit No   Document
     
99.1   Press Release dated August 7, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 7, 2023 BIMI International Medical Inc.
   
  By: /s/ Tiewei Song
  Name:  Tiewei Song
  Title: Chief Executive Officer

 

 

 

 

 

 

Exhibit 99.1

 

BIMI International Medical Inc. Announces Strategic Partnership by its Phenix Bio Inc. Subsidiary with China Duty Free Group

NEW YORK, NY, Aug. 07, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ: BIMI, “BIMI”), a leading global provider of healthcare services and innovative medical solutions, today announced the formation of a strategic partnership between its subsidiary, Phenix Bio Inc. (“Phenix”) and China Duty Free Group (“CDFG”), one of the largest and most influential state-owned duty-free retail enterprises in China.

The Purchase Agreement between Phenix and CDFG, which became effective on August 1, 2023, provides that CDFG will distribute a selection of Phenix’s healthcare products across all of its retail stores for a one-year term.  

Under the term of the agreement, a selection of Phenix’s high-quality dietary supplements will be made available to Chinese consumers through CDFG's extensive network of duty-free retail locations in airports, cruise terminals, and downtown stores. The partnership aims to improve the accessibility of world-class dietary supplements to China's growing population, while further expanding BIMI and Phenix’s footprint in the Asian market.

A signing ceremony was held at BIMI’s headquarters in New York City where representative from both parties, including BIMI's Chief of Staff, Symington Smith and CDFG executives, attended.

"We are thrilled to partner with China Duty Free Group, a company that shares our commitment to excellence and innovation in the healthcare sector," said Tiewei Song, CEO of BIMI. "This partnership represents a significant opportunity for our company to leverage CDFG's extensive distribution network, while offering Chinese consumers access to our best-in-class products and services.”

About BIMI International Medical Inc.
BIMI International Medical Inc. (NASDAQ: BIMI) is a leading global provider of healthcare services and innovative medical solutions, dedicated to improving patient outcomes and ensuring the highest standards of medical care. With a diverse portfolio of products and services, BIMI International Medical Inc. is committed to enhancing the overall healthcare experience for patients, healthcare professionals, and institutions alike. For more information, please visit www.usbimi.com

About China Duty Free Group
China Duty Free Group (CDFG) is one of the largest and most influential state-owned duty-free retail enterprises in China. With a vast network of retail locations in airports, cruise terminals, and downtown stores, CDFG is dedicated to providing travelers and consumers with a world-class shopping experience, offering a diverse range of high-quality products and services.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of BIMI International Medical Inc.'s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the integration of acquired businesses and other risks detailed in BIMI International Medical Inc.'s filings with the Securities and Exchange Commission. BIMI International Medical Inc. assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Investor Relations Contact:
Vinson Smith
vinson@usbimi.com
949 981 6274

 

v3.23.2
Cover
Aug. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 07, 2023
Entity File Number 001-34890
Entity Registrant Name BIMI International Medical Inc.
Entity Central Index Key 0001213660
Entity Tax Identification Number 02-0563302
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 725 5th Avenue
Entity Address, Address Line Two 15th Floor
Entity Address, Address Line Three 15-01
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code 212
Local Phone Number 542 0028
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol BIMI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false

BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more BIMI International Medical Charts.
BIMI International Medical (NASDAQ:BIMI)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more BIMI International Medical Charts.